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The adipose tissue participates in the regulation of energy homeostasis as an important
endocrine organ that secretes a number of biologically active adipokines, including
adiponectin. Recently we developed and characterized a first-in-class peptide-based
adiponectin receptor agonist by using in vitro and in vivo models of glioblastoma and
breast cancer (BC). In the current study, we further explored the effects of peptide ADP355
in additional cellular models and found that ADP355 inhibited chronic myeloid leukemia
(CML) cell proliferation and renal myofibroblast differentiation with mid-nanomolar IC50
values. According to molecular modeling calculations, ADP355 was remarkably flexible
in the global minimum with a turn present in the middle of the peptide. Considering
these structural features of ADP355 and the fact that adiponectin normally circulates
as multimeric complexes, we developed and tested the activity of a linear branched
dimer (ADP399). The dimer exhibited approximately 20-fold improved cellular activity
inhibiting K562 CML and MCF-7 cell growth with high pM—lownM relative IC50 values.
Biodistribution studies suggested superior tissue dissemination of both peptides after
subcutaneous administration relative to intraperitoneal inoculation. After screening of a
397-member adiponectin active site library, a novel octapeptide (ADP400) was designed
that counteracted 10–1000nM ADP355- and ADP399-mediated effects on CML and BC
cell growth at nanomolar concentrations. ADP400 induced mitogenic effects in MCF-7
BC cells perhaps due to antagonizing endogenous adiponectin actions or acting as an
inverse agonist. While the linear dimer agonist ADP399 meets pharmacological criteria
of a contemporary peptide drug lead, the peptide showing antagonist activity (ADP400)
at similar concentrations will be an important target validation tool to study adiponectin
functions.
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INTRODUCTION
Adiponectin is a relatively large (244 amino acid) cytokine
that is normally produced by the fat tissue and found in
Abbreviations: AdipoR, adiponectin receptor; All, allyl; ADP355, first genera-
tion adiponectin receptor peptide agonist; ADP399, second generation adiponectin
receptor agonist, linear dimer of ADP355; ADP400, adiponectin receptor
antagonist/inverse agonist; AMPK, 5′ adenosine monophosphate-activated pro-
tein kinase; BC, breast cancer; BMI, body mass index; BSA, bovine serum
albumin; Chex, 1-amino-cyclohexane carboxylic acid; CML, chronic myeloid
leukemia; Dab, 2,3-diamino butyric acid; DIC, diisopropyl-carbodiimide; dPCA,
dihedral principal component analysis; DMEM, Dulbecco’s modified Eagle’s
medium; DMF, dimethyl formamide; EC, effective concentration; ELISA, enzyme-
linked immunosorbent assay; FBS, fetal bovine serum; Fmoc, 9-fluorenyl-
methoxycarbonyl; GLP, glucagon-like peptide; HOBt, 1-hydroxy-benzotriazole; IC,
human serum at concentrations of 2–20μg/mL making it one
of the most abundant proteins in systemic circulation (Arita
et al., 1999; Ryan et al., 2003; Chiarugi and Fiaschi, 2010).
Circulating adiponectin levels are inversely correlated with body
mass index (BMI) (Galic et al., 2010). Adiponectin is consid-
ered a protective hormone exhibiting beneficial effects against
insulin resistance, cardiovascular disease, inflammatory condi-
inhibitory concentration; ip, intraperitoneally; MALDI TOF-MS, matrix-assisted
laser ionization/desorption time-of-flight mass spectrometry; MBHA, 4 methyl-
benzhydrylamine; ObR, leptin receptor; PBS, phosphate buffered saline; REMD,
replica-exchange molecular dynamics; RP-HPLC, reversed-phase high perfor-
mance liquid chromatography; SMA, α-smooth muscle actin; sc, subcutaneously;
SE, standard error; TFA, trifluoroacetic acid.
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tions, and cancer (Barb et al., 2007; Schaffler et al., 2007; Ziemke
and Mantzoros, 2010). The protein circulates in trimeric, hex-
americ, and higher order complexes although less abundant
monomeric forms have been also detected (Fang and Sweeney,
2006). Two adiponectin receptors, AdipoR1 and AdipoR2, have
been identified. Both are seven-transmembrane domain pro-
teins containing an N-terminal intracellular portion and the C-
terminal extracellular-domain (Yamauchi et al., 2003; Kadowaki
and Yamauchi, 2011).
Although some anti-diabetic drugs (e.g., metformin, a
biguanide) (Hadad et al., 2008; Gonzalez-Angulo and Meric-
Bernstam, 2010) as well as caloric restriction (Jiang et al., 2008)
can partially mimic adiponectin action and induce AMPK (5′
adenosine monophosphate-activated protein kinase) signaling
in cancer tissues, specific, and selective compounds targeting
AdipoR were not available before 2011. Adiponectin protein-
based biological modulators are still not available, partly due
to difficulties in converting the full size adiponectin protein
into a viable systemic regulator. The main reason of the non-
druggability of adiponectin protein is the extreme insolubility
of the C-terminal domain and larger peptide fragments thereof
(Otvos et al., 2011a). Consequently, we attempted to produce
small peptides that would produce similar or superior biological
effects as adiponectin protein but would be suitable for pharma-
cological modifications. Adding to the difficulties in experimental
design and drug development, AdipoR1 and AdipoR2 also form
homomeric complexes that influence their ligand binding prop-
erties (Almabuada et al., 2013) and make these proteins poorly
soluble chemical entities.
In 2011 we reported on the identification of the adiponectin
active site and the design and functional characterization of
adiponectin-based peptide compounds for the activation of
AdipoR using glioma and breast cancer (BC) model systems
(Otvos et al., 2011a). The lead peptide, the 10-mer ADP355, pri-
marily acts through AdipoR1 and induces typical adiponectin
signaling pathways in cancer cells (Otvos et al., 2011a). Similar
to full-sized adiponectin and its C-terminal globular domain,
peptide ADP355 exhibits cell-type specific cytostatic activity on
glioma and BC cells. Notably, however, AMPK phosphorylation,
believed to be amarker of adipokine function, is observed only for
MCF-7 hormone sensitive but not MDA-MB-231 hormone resis-
tant BC cells. The cell-type dependence of AMPK involvement
in adiponectin signaling and the differences in the cellular effects
of various adiponectin protein preparations were noted earlier
(Wijesekara et al., 2010). ADP355 shows no toxic properties to
normal mice up to a 10mg/kg bolus intraperitoneal (ip) dose.
ADP355 contains 4 unnatural amino residues, and due
to these modifications the peptide (peptidomimetic) shows
remarkable stability in human serum. When administered ip at
0.5–1mg/kg/day, peptide ADP355 exhibits typical adiponectin
effects in rodents, that is stabilization of metabolic func-
tions, and prevention of brain injury caused by HIV protease
inhibitors (Pepping et al., 2014) and reduces weight gain and
improves biomarker pattern in animals on long-term high-fat diet
(Wintrob et al., 2013). A recent study used ADP355 as a refer-
ence compound to identify non-peptidic AdipoR agonists from
a 10,000-member natural product library, but even the best hit
retained μM IC50 activities (Sun et al., 2013). Another small
molecule library identified an orally available AdipoR agonist
called AdipoRon, but the reported lowmicromolar receptor bind-
ing kinetics and mid-micromolar in vitro efficacies are even more
inferior compared to the earlier reported non-peptide ligands
(Okada-Iwabu et al., 2013).
Currently AdipoR antagonists do not exist but could find
application in diseases characterized by adiponectin overabun-
dance. For example, serum adiponectin levels are reproducibly
higher in severe rheumatoid arthritis patients than in the control
group (Ebina et al., 2009). The expression levels of both AdipoR
subtypes are also remarkably higher in lesional than in non-
lesional areas of osteoarthritis cartilage (Kang et al., 2010). Thus,
an AdipoR antagonist would potentially offer a novel treatment
option to arthritic diseases. Perhaps more realistically, an AdipoR
antagonist would represent a highly-awaited target validation tool
for AdipoR agonist drug development.
Although the signaling and growth modifying effects of the
full protein is frequently studied in skeletal muscle, cardiovas-
cular, liver, and lung cell lines, the correct evaluation of the
readout of these assays are not without controversy (Dadson et al.,
2011). First, agents that induce endogenous adiponectin produc-
tion can have opposite effects compared to adding exogenous
adiponectin as was shown on fibrogenesis in hepatic stellate cells
(Potter andMezey, 2007). Second, in mouse primary hepatocytes,
adiponectin can exert in vitro functions independent of signal-
ing pathways detected in vivo (Miller et al., 2011). Third, and
most significant to synthetic peptides, proper signaling, and inhi-
bition of smoothmuscle cell proliferation by adiponectin requires
proteolytic cleavage to shorter forms (Fuerst et al., 2012). Thus,
for evaluating new ADP355 peptide derivatives and comparing
their cellular functions, we keep using cancer cell models that
work satisfactorily and consistently in our hands and proliferation
inhibition/enhancement as assay readout.
At a very high dose (10mM), peptide ADP355 prevents
stiffness-associated focal adhesion kinase phosphorylation in
myofibroblasts grown on soft surfaces better than 10μg/mL full-
sized adiponectin (Kumar et al., 2014). The first goal of the cur-
rent studies was to investigate the utility of ADP355 in non-solid
neoplasms and fibrotic diseases, and improve the IC50 of AdipoR
agonists to high picomolar-low nanomolar levels. Recognizing
the high demand for an AdipoR antagonist for target valida-
tion in biomedical research (and potentially to treat autoimmune
diseases), our second goal was to convert the AdipoR agonist
ADP355 into an AdipoR antagonist. For this purpose we used
the technology that was successful in turning leptin-based ObR
agonist peptides into picomolar antagonists (Otvos and Surmacz,
2011). In the current report, we describe the development of
second generation AdipoR cellular response modifying peptides
(peptidomimetics), with agonist and antagonist activity levels
expected of contemporary drug leads.
MATERIALS AND METHODS
PEPTIDE SYNTHESIS
The peptides listed in Table 1 were assembled on a SYRO2000
(MultiSynTech GmbH, Witten, Germany) multiple synthe-
sizer with standard 9-fluorenylmethoxycarbonyl/tert-butyl
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Table 1 | Adiponectin receptor response modifier peptides.
Number/Name Sequencea Function Monoisotopic mass [M + H]+
(calculated/measured)
Retention
time (min)
355 H-DAsn-Ile-Pro-Nva-Leu-Tyr-DSer-Phe-Ala- First generation agonist 1109.59/1109.60 28.5
ADP355 DSer-NH2 (published)
DY675-ADP355 1797.84/1797.87
398
ADP355 + C1
Cyclic dimer
Cyclo (DAsn-Ile-Pro-Nva-Leu-Tyr-DSer-Phe-
Ala-DSer-His-Pro-DAsn-Ile-Pro-Nva-Leu-Tyr-
DSer-Phe-Ala-DSer-His-Asp)-OH
Control cyclic peptide
to verify structure
calculations (new)
2670.33/2670.24 32.8
399 (H-DAsn-Ile-Pro-Nva-Leu-Tyr-DSer-Phe-Ala- Second generation 2769.44/2769.48 30.2
ADP355 + C1 DSer-His-Pro)2-Dab-NH2 (branched) agonist (new)
Linear dimer DY675-ADP355 + C1 3457.61/3457.67 (single label)
400
Chex-DSer-8
H-Chex-Gly-Leu-Tyr-DSer-Phe-Ala-DSer-
NH2
First generation
antagonist (new)
868.45/868.45 26.6
500
Branched trimer
(H-DSer-Asn-Ile-Pro-Nva-Leu-Tyr-DSer-Phe-
Ala-Tyr-His-Pro)2-Dab-Dab(H-DSer-Asn-Ile-
Pro-Nva-Leu-Tyr-DSer-Phe-Ala-Tyr-His-Pro)-
NH2
Control trimeric agonist
(new)
4686.41/4686.44
While the chemical and biological properties of ADP355 have been publisher earlier, the two dimeric agonists, the trimeric peptide and the antagonist are new to
this study.
aChex, Dab, Nva, and D denote 1-amino-cyclohexane carboxylic acid, 2,3-diamino butyric acid, norvaline, and D-amino acids, respectively.
(Fmoc/tBu)-chemistry. ADP355 (peptide 355), Chex-DSer-8
(400), ADP355 linear branched dimer (399), ADP355 cyclic
dimer (398), and the trimeric (500) peptides were synthe-
sized on Rink amide 4-methylbenzhydrylamine (MBHA,
0.6mmole/g; Iris Biotech GmbH, Marktredwitz, Germany)
(355, 400), TentaGel R RAM (0.19mmole/g; Rapp Polymere
GmbH, Tuebingen, Germany) (399, 500), and Fmoc-Asp
(PEG-PS)-OAll (0.16mmole/g; PerSeptive Biosystems GmbH,
Hamburg, Germany) (398) resins on a 25μmole scale. Amino
acid derivatives (Iris Biotech or Orpegen Pharma GmbH,
Heidelberg, Germany) were activated in situ with diisopropy-
carbodiimide (DIC) in the presence of 1-hydroxybenzotriazole
(HOBt) (Knappe et al., 2011). The C-terminal Asp-OAll of
the ADP355 cyclic dimer was deprotected using 3 equiva-
lents of tetrakis (triphenylphosphine)palladium (0) catalyst
(15.5 g/L, w/v) in a mixture of chloroform, acetic acid, and
4-methylmorpholine (37:2:1, v/v/v) under nitrogen atmosphere
for 2 h. The resin was washed twice with (i) N,N-diisopropyl-
ethylamine (0.5%) in dimethyl-formamide (DMF; Biosolve,
Valkenswaard, Netherlands), (ii) sodium diethyl-carbamate
in DMF (0.5%), (iii) HOBt in DMF (0.25 M) and (iv) DMF.
Cyclization was achieved by activation with 2 equivalents of
DIC/HOBt. The DY675 fluorophore (674 nm absorption/688 nm
emission) was coupled as pre-formed N-hydroxy succinimide
ester to resin-bound ADP355 and the linear dimer. The final
peptides were cleaved with trifluoroacetic acid (TFA) containing
12.5% (v/v) of a scavenger mixture (ethane dithiol, m-cresole,
thioanisole, and water, 2.5:5:5:5, v/v/v/v) and precipitated
with cold diethyl ether after 2 h. The precipitated peptides
were washed twice with cold diethyl ether, dried, and purified
by reversed-phase high performance liquid chromatography
(RP-HPLC) using a linear aqueous acetonitrile gradient in
the presence of 0.1% (v/v) TFA as ion pair reagent (Jupiter
C18-column, 10mm internal diameter, 250mm length, 5μm
particle size, 30 nm pore size; Phenomenex Inc., Torrance,
USA). The final products were characterized by RP-HPLC
and matrix-assisted laser ionization/desorption time of flight
mass spectrometry (MALDI-TOF-MS; 4700 Proteomic ana-
lyzer; Applied Biosystems GmbH, Darmstadt, Germany) using
α-cyano-4-hydroxycinnamic acid (Bruker Daltonics GmbH,
Bremen, Germany; 4 g/L in 60% aqueous acetonitrile containing
0.1% TFA) as matrix.
SERUM STABILITY
For serum stability studies (Powell et al., 1993) 10μL of an
aqueous peptide stock solution (3mg/mL) was added to 390μL
pooled mouse serum in triplicate. The peptide-serum mixtures
were thermostated at 37◦C. After 0, 30, 120, and 240min, 95μL
aliquots were mixed with 25μL trichloroacetic acid (15%, w/v)
and incubated for 10min on ice. The precipitated proteins
were separated by centrifugation (5min, 12,000× g, Eppendorf
MiniSpin). The supernatant (90μL) was neutralized with 8.5μL
aqueous sodium hydroxide solution (1 M) and mixed with 3%
aqueous acetonitrile containing 0.1% TFA (121.5μL). After cen-
trifugation (5min, 12,000× g, Eppendorf MiniSpin) a 100μL
solution was analyzed by RP-HPLC using a Jupiter C18 col-
umn (2.0mm inner diameter, 150mm length, 5μm particle size,
30 nm pore size; Phenomenex, Torrance) on a Beckman Gold
HPLC System at 60◦C. The gradient from 0.1%TFA in water (elu-
ent A) to 60% acetonitrile in 0.1% aqueous TFA (eluent B) was
developed using 1% B/min and the amide bond was monitored at
214 nm.
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CELL PROLIFERATION
MCF-7 BC and K562 chronic myeloid leukemia (CML) cells were
grown in standard RPMI 1640 medium. Seventy-five thousand
MCF-7 and 100,000 K-562 cells grown in RPMI 1640 medium
containing 10% fetal bovine serum (FBS, for MCF-7) or 0.5%
bovine serum albumin (BSA, for K562) were seeded into wells
of 24-well culture plates. After 24 h, MCF-7 cells were shifted to
K562 medium (serum free). After an additional 24 h, the cul-
tures were treated with various concentrations of peptides or a
mixture of peptides for 72 h and counted. The assays were done
in triplicates and repeated twice from different cell preparations.
The cell numbers were expressed as means ± standard error (SE).
Statistical analysis was done with a SlideWrite graphical software
package (Encinitas, USA).
RENAL MYOFIBROBLAST DIFFERENTIATION
Renal interstitial fibroblasts were isolated from fibrotic rat kidneys
using explanting methods described previously (Hewitson et al.,
2001). Kidney tissue for explants was derived from obstructed
rat kidneys 3 days post-unilateral ureteric obstruction. Cultures
were propagated by mincing the tissue into pieces, placing them
into gelatin- (Sigma, St. Louis, USA) coated Petri-dishes (Nunc,
Roskilde, Denmark), and adding DMEM (Dulbecco’s modified
Eagle’s medium, Sigma) supplemented with 10% FBS (Bovogen,
Melbourne, Australia) and penicillin/streptomycin antibiotics
(MP Biomedicals, Santa Ana, USA). Explants were maintained
at 37◦C with media being changed twice a week. At conflu-
ence, primary outgrowths were trypsinized and subcultured for
subsequent experiments. Subcultured cells were characterized
cytochemically and by growth characteristics as fibroblasts, a
proportion of which were defined as myofibroblast (activated
fibroblasts) based on positive staining for α-smooth muscle actin
(SMA) (Karamifar et al., 2013).
For quantitative studies, cells were grown on cover slips (Nunc,
Roskilde, Denmark) to semi-confluence and exposed to con-
trol media or media supplemented with the ADP355 peptide
in triplicate. After 48 h cells grown on coverslips were fixed in
ice-cold methanol. Following blocking with non-immune serum
and incubation with anti-SMA, (Dakopatts, Glostrup, Denmark)
cover slips were washed in phosphate buffered saline (PBS), incu-
bated with biotinylated anti-mouse immunoglobulin (Vector,
Burlingame, USA), washed in PBS, and incubated with avidin–
biotin complex (Vector) and 3,3′-diaminobenzidine (Sigma).
Finally, cells were counterstained with Harris haematoxylin (BDH
Kilsyth, Australia) and mounted with Aquamount Gurr (BDH).
Cells with positive staining were enumerated and expressed as a
percentage of total cells counted.
IN VIVO BIODISTRIBUTION
Twenty μg of DY675-coupled peptides ADP355 (355) and lin-
ear dimer (399) were injected ip or subcutaneously (sc) into
anesthetized female Skh1 hairless mice. While sleeping, the ani-
mals were placed into the fluorescence microscope chamber. One
minute-long fluorescence exposure pictures were taken with a
Kodak 4000 MM camera set to 700 nm emission wavelength
immediately after inoculating the mice, 10min later and 1 h after
drug administration. The mice were photographed both from
their abdominal and dorsal sides (Otvos et al., 2011b). All exper-
iments with vertebrate animals were approved by the Animal
Health Committee of Semmelweis Medical School.
REPLICA EXCHANGE MOLECULAR DYNAMICS SIMULATIONS
Conformational properties of adiponectin analogs were stud-
ied with the GROMACS 4.5.7 software package (Hess et al.,
2008) using REMD simulations (Sugita and Okamoto, 1999).
For the simulations the AMBER99SB-ILDN-NMR force field
parameters (Li and Bruschweiler, 2010) were used. Atom types
and partial atomic charges for norvaline were derived from
leucine and isoleucine. Force field parameters for Chex were
obtained from Grubisic et al. (2012). Atom types for Dab were
derived from lysine and the atomic partial charges were calcu-
lated with YASARA AutoSMILES (www.yasara.org/autosmiles).
Peptides were solvated with TIP3P waters (Jorgensen et al., 1983)
in a truncated dodecahedron, Na+ and Cl− ions were added to
neutralize the charge of the systems and the final concentration
of NaCl was adjusted to 150mM. Simulations were 150 ns long,
integration time step was 2 fs and all bond lengths were con-
strained using the LINCS (Hess et al., 1997) method. Electrostatic
interactions were calculated with the particle mesh Ewald method
(Darden et al., 1993) using 1.0 nm cutoff and the van der Waals
interactions were switched off between 0.7 and 0.9 nm. Non-
bonded pair lists were updated at every 0.02 ps. Simulations were
performed in an NPT (constant number of particle, pressure, and
temperature) ensemble by coupling the system to a bath of con-
stant 1 bar pressure with 1.0 ps coupling time. The peptides and
water plus NaCl molecules were coupled separately to external
heath bath with 0.1 ps relaxation time. Temperatures ranged from
290 K to 383 K, using 20% acceptance ratio, the number of repli-
cas were calculated using the http://folding.bmc.uu.se/remd/ web
server (Patriksson and Van der Spoel, 2008). Exchanges between
neighboring replicas were attempted at every 2 ps.
Convergence of an REMD simulation was determined by cal-
culating the configurational entropy of a peptide chain in a
demultiplexed trajectory using the quasi-harmonic approxima-
tion (Andricioaei and Karplus, 2001) in the essential dynamics
analysis module of GROMACS. Results presented here are from
the trajectories at 300 K. During the simulations for peptides 25,
355, and 400 the configurational entropy reached a plateau after
100 ns, therefore, the last 50 ns of these trajectories were used for
subsequent analysis. For peptide 399, the configuration entropy
reached a plateau for the last 78 ns, therefore, this portion of the
trajectory was analyzed. The dihedral principal component anal-
ysis (dPCA) method (Mu et al., 2005) was used to explore the free
energy landscape of peptides using the first two principal compo-
nents dPCA1 and dPCA2. The low energy structures on the free
energy surfaces were determined by clustering the data with the R
3.0.2 program (R Core Team R, 2013) using the partition around
medoid clustering methods with 10 clusters.
RESULTS
SCREENING OF ADP355 IN DISEASES INVOLVING AdipoR ACTIVITY
Chronic myeloid leukemia
To investigate the utility of AdipoR agonists to non-solid neo-
plasms, we studied the effects of peptide ADP355 (peptide 355,
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Table 1) on the proliferation of the CML cell line K562. When
added at 10 nM–1μM, ADP355 reduced the 3-day proliferation
rate in a dose-dependentmanner (Figure 1).Maximum effect was
observed at 1μM that corresponded to 20–40% reduction in sur-
viving cells (across 3 independent assays) and compared favorably
to a 20–25% maximum cell death for the MCF-7 BC model in
the earlier study (Otvos et al., 2011a). The relative IC50 of our
first assay was estimated at 200 nM indicating that higher ADP355
concentrations are required to inhibit CML than BC cells where
the IC50 is 10–50 nM (in hormone responsive and triple negative
BC, respectively). At later assays, K562 cells became 10-fold more
sensitive to AdipoR agonist treatment either due to stress imposed
by low nutrient media conditions, or due to the increased number
of cell passages that potentially reflected the increased expression
of AdipoR1 during CML pathogenesis (Ozturk et al., 2012).While
at later passages 10 nM concentration of ADP355 showed some
activity, maximum growth inhibition was consistently detected at
1μM. As seen earlier for this peptide with glioblastoma and BC
cells (Otvos et al., 2011a) and for leptin receptor (ObR) antag-
onists (Beccari et al., 2013) at high dose (10μM) the pharma-
cological effects were reversed, and ADP355 inhibited CML cell
growth to a smaller extent (Figure 1). Similar bell-shaped dose-
response curves were observed for a non-peptide agonist of the
glucagon-like peptide (GLP) 1 receptor (Knudsen et al., 2007) and
a peptidomimetic of the granulocyte-colony stimulating factor
(Tian et al., 1998). For the GLP-1 receptor agonist the high dose
reversal of the pharmacological profile was explained as a non-
specific antagonistic effect. Based on analogy with leptin receptor
agonists (Kovalszky et al., 2010), such high dose antagonistic
effects of our adiponectin peptides cannot be excluded.
Myofibroblast differentiation
First we studied the effects of ADP355 (peptide 355) on kid-
ney fibroblast proliferation. Treatment with 10 nM–1μMpeptide
inhibited the growth by 28–43% but no concentration depen-
dence could be observed and the deviation among parallels were
relatively high (data not shown). A clearer picture emerged when
we studied α-smooth muscle actin (SMA) positive cells, a mea-
sure of fibroblast activation (inset to Figure 2). ADP355 inhibited
renal myofibroblast differentiation by 4, 11 ± 4, and 14 ± 2%
when added at 10, 100 nM, and 1μM, respectively (Figure 2).
While these results do not warrant the continued research of
ADP355 in kidney disease, they verify the involvement of AdipoR
in tissue fibrosis and suggest that improved AdipoR agonists may
find utility in fibrotic diseases.
DESIGN OF AN AdipoR ANTAGONIST
Based on the success of our first-in-class AdipoR agonist ADP355
and recognizing the need for a similar AdipoR antagonist, we
modified the composition of ADP355 to attenuate AdipoR func-
tions and signaling. The starting point of the design was the
activity of the 396-member peptide library we made earlier and
from which the ADP355 agonist was selected, and a new cen-
tral hexamer named peptide 3–8 (Table 2). Biological activity
screening in MCF-7 cells suggested that the nanomolar ago-
nistic activity can be restricted to the C-terminal octapeptide
fragment, and the residues C-terminal of Pro3 bind but do not
activate AdipoR. While Pro1 in the C-terminal octamer (Pro3
in ADP355) is replaceable, Gly2, Tyr4, Phe6, Ala7, and DSer8
should be kept for binding. Because Nva3 recovers activation,
Leu, the original amino acid in native adiponectin, should be
FIGURE 1 | Effect of adiponectin receptor agonist peptides on
adiponectin receptor-positive K562 chronic myeloid leukemia
cells in vitro. The peptides (355, 398, and 399) were added in
10 nM–10μM concentration. The empty triangle indicates cell
growth without any peptide added. The relative IC50 line is
drawn halfway between uninhibited cell growth and maximal
growth inhibition by the peptides (lowest level of cell growth in
the current assay).
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used in this position. DSer5 was added to ADP355 (as DSer7)
for increased stability, and as this residue promotes binding but
does not support agonist functions, it should be kept in the new
AdipoR antagonist. In the new antagonist Pro1 was replaced with
FIGURE 2 | Inhibition of renal myofibroblast differentiation by
adiponectin receptor agonist peptide ADP355. The filled circles
represent individual data points. The inset shows how the effects of 1μM
ADP355 was quantified by measuring the proportion of fibroblast cultures
staining brown for α-smooth muscle actin (SMA), a marker of myofibroblast
differentiation, and therefore fibroblast activation (compare with Materials
and Methods).
1-amino-cyclohexane carboxylic acid (Chex1), extremely useful
as an N-terminal cyclic aliphatic amino acid mimic in designer
antibacterial peptides (Cudic et al., 2002). These considerations
led to derivative 400 (ADP400), H-Chex-Gly-Leu-Tyr-DSer-Phe-
Ala-DSer-NH2 (we called it Chex-DSer-8), as a potential AdipoR
antagonist (Tables 1, 2).
SCREENING THE BIOLOGICAL ACTIVITY OF ADP400, Chex-DSER-8
While obviously we do not intend to use the AdipoR antagonist
as an oncogenic agent, for the first screen of general antagonis-
tic properties we investigated the ability of peptide Chex-DSer-8
(peptide 400) to recover the proliferation of different neoplastic
cell lines known to be inhibited by the AdipoR agonist ADP355
(peptide 355).
Chronic myeloid leukemia model
Similar to the findings in the first paragraph of this RESULTS
section, ADP355 (355) inhibited K562 growth with maximum
efficacy observed at 1μM concentration. ADP400, Chex-DSer-8,
counteracted ADP355 actions against K562 proliferation dose-
dependently (Figure 3). However, as opposed to the 200 nM
agonistic activity of ADP355, the IC50 of Chex-DSer-8 was just
barely below 1μM (920 nM) and the pharmacological profile did
not reverse at high (in this case 10μM) peptide concentrations.
Breast cancer model
ADP355 (peptide 355) attenuates MCF-7 BC cell growth by
20–25% when added at 100 nM concentration (Otvos et al.,
Table 2 | Activity of members of a targeted agonist library that served as a basis of the design of Chex-DSer-8, the first-in-class adiponectin
receptor antagonist peptidomimetic.
ID Peptide sequencea Agonistic
activity
Structural considerations
For length
25 Asn-Ile-Pro-Gly-Leu-Tyr-Tyr-Phe-Ala-Tyr Normal Antagonist is inside peptide 25 (P25)
26 Pro-Gly-Leu-Tyr-Tyr-Phe-Ala-Tyr-His-Ile Normal Inside 3–10 of P25
3–8 Pro-Gly-Leu-Tyr-Tyr-Phe None Keep residues 9–10 of P25
For antagonist architecture
24 His-Cys-Asn-Ile-Pro-Gly-Leu-Tyr-Tyr-Phe Normal Residues C-term of Pro (until Tyr10 in P25)
156 His-Cys-Asn-Nva-Pro-Gly-Leu-Tyr-Tyr-Phe None bind but do not activate
Antagonist positional refinements
Pro1-Tyr8
92 Cpc-Gly-Leu-Tyr-Tyr-Phe-Ala-Tyr-His-Nva Normal Pro1 is replaceable
157 Asn-Ile-Pro-Nva-Leu-Tyr-Tyr-Phe-Ala-Tyr Increased Keep native Gly in position 2
288 His-Cys-Asn-Nva-Pro-Gly-Nva-Tyr-Tyr-Phe Reduced Nva in position 3 recovers activation; keep
Leu3
290 Pro-Gly-Leu-DSer-Tyr-Phe-Nva-Tyr-His-Ile None Keep Tyr4 and Ala7 for binding
223 Asn-Ile-Pro-Gly-Leu-Tyr-DSer-Phe-Ala-Tyr Weakest among
P25 analogs
DSer in position 5 for increased stability
binds but does not support agonist function
90 DLys-Cys-Asn-Ile-Pro-Gly-Leu-Tyr-Tyr-Cpc Reduced Keep Phe in position 6 for binding
91 DAsn-Ile-Pro-Gly-Leu-Tyr-Gly-Phe-Ala-DSer Normal DSer in position 8 retains binding
aCpc, Nva, and D denote 1-amino cyclopentane carboxylic acid, norvaline, and D-amino acids, respectively.
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FIGURE 3 | Peptide Chex-DSer-8 (ADP400) counteracts the K562 cell
growth inhibitory effects of peptide ADP355 with a relative IC50 of
920nM. The empty and filled triangles show the cell growth with no
peptide added (uninhibited cell growth) and with 1μM ADP355 alone (full
growth inhibition), respectively.
2011a). In an experiment identical to that presented for K562
cells, Chex-DSer-8 (400) counteracted ADP355 cytostatic actions
in MCF-7 cells in a dose-dependent manner with full activity
observed at 100 nM concentration and an IC50 of approximately
15 nM (data not shown). This value is somewhat, but not signifi-
cantly, higher than the IC50 figure of ADP355 itself againstMCF-7
cells suggesting that in this concentration range Chex-DSer-8
(ADP400) is indeed an AdipoR antagonist and both peptides
likely interact with the same receptor with similar avidity. The
combination of the CML and BC findings suggests that modula-
tion of AdipoR activity with our peptides is more pronounced for
solid tumors than in hematologic cancers, and potentially reflect-
ing low AdipoR levels in CML (Ozturk et al., 2012). Nevertheless,
these data also show that peptide 400, Chex1-DSer-8, can be used
with confidence as a sensitive AdipoR target validation tool in
different biological models.
Up to this point we looked at the effects of the AdipoR antago-
nist ADP400, Chex-DSer-8, (ADP400) in the presence of agonist
ADP355. However, MCF-7 cells express adiponectin themselves
(Jarde et al., 2009), and it is possible that AdipoR antago-
nists promote cancer cell growth by interfering with autocrine
adiponectin. It needs to be added that this hypothesis is untrue
for our ObR antagonists that do not promote or inhibit MCF-7
cell growth when used alone (without leptin) in a wide concen-
tration range (Otvos et al., 2011b,c). We repeated the MCF-7
growth promotion/inhibition assay with the adiponectin-derived
peptides twice and noticed that on cell passage Chex-DSer-8
(peptide 400) at 100 nM concentration may have mitogenic prop-
erties. We incubated cells with leptin protein alone to quantify
the additional level of cell proliferation, and indeed, 10 nM lep-
tin promoted MCF-7 cell growth, as always, by 10% (Figure 4).
Similar to earlier results, the AdipoR agonist ADP355 (355)
at 100 nM attenuated MCF-7 cell growth with 90% statisti-
cal confidence (p = 0.092). Likewise, ADP400, Chex-DSer-8, at
FIGURE 4 | Effects of adiponectin-derived peptides on the proliferation
of MCF-7 cells. The peptides (ADP355 and ADP400, Chex-DSer-8) were
tested at 100 nM concentration. PBS indicates cell growth without any
additives. Leptin protein added at 10 nM was used as a positive control for
exogenous mitogen actions. Statistically significant differences (p ≤ 0.1 and
0.01) between samples are indicated by single and triple asterisks,
respectively.
100 nM completely ameliorated ADP355-induced growth inhibi-
tion (p = 0.003). However, in this instance cell proliferation was
more extensive than without any peptide added and reached the
extent of cell growth stimulated by the mitogen leptin. This effect
was probably due to inhibition of the action of both exogenous
and endogenous AdipoR agonists, as without ADP355 present,
the AdipoR antagonist promoted cell growth to an identical
degree.
MOLECULAR MODELING OF THE NATIVE ADIPONECTIN ACTIVE SITE,
THE ADP355 AGONIST AND THE ADP400 Chex-DSER-8 ANTAGONIST
Dihedral principal component analysis of the last 50 ns of
the replica-exchange molecular dynamics (REMD) trajectory
revealed that the free energy landscape has multiple minima with
one deep local minimum (Figure 5). The lowest energy structures
of the native adiponectin active site (peptide 25, Ile-Pro-Gly-
Leu-Tyr-Tyr-Phe-Ala, Table 2) assumed a mixture of random
and α-helical conformations in the global minimum and were
in predominantly α-helices in the rest of the low energy struc-
tures (Figure 5). Turn conformations were also located in higher
energy local minima, but these occupied shallow configurational
space. Taken together the helical structure seemed to be quite
stable. In contrast, on the free energy surface of ADP355 more
minima were observed (Figure 5). The free energy surface was
shallower than that of peptide 25 indicating remarkable flexibility
of the peptide. In the global minimum (Figure 6) a turn con-
formation was present in the middle of the peptide (resembling
a β-hairpin conformation). The other structures were mostly
random in the higher energy minima. Apparently, the designer
peptidomimetic ADP355 was considerably more flexible than the
native fragment, and such could fit into the AdipoR groove with
smaller energy expense than the unmodified parent peptide.
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FIGURE 5 | Free energy surfaces (in kJ mol−1) of adiponectin peptide
analogs as a function of the first two dihedral principal components. The
representative backbone structures located at different minima are indicated
by an arrow, N indicates the N-terminus of a peptide chain, NA an NB on (D),
respectively, indicate the N-terminus of chains A and B. The corresponding
color code for the free energy values are plotted as a bar at the right side of
the surfaces. Color codes for secondary structures: pink, α-helix; blue,
310-helix; yellow, β-sheet; cyan, β-bend; gray, random meander. (A) Free
energy surfaces (in kJ mol−1) of native peptide 25; (B) free energy surfaces
(in kJ mol−1) of first generation agonist peptide ADP355 (355); (C) free
energy surfaces (in kJ mol−1) of antagonist peptide 400; (D) free energy
surfaces (in kJ mol−1) of linear branched dimeric peptide 399.
The free energy surface for peptide 400 (Chex-DSer-8 antag-
onist) was even more shallow than the previous two surfaces
indicating a flexible structure, but a central 310-helix con-
formation dominated the global minimum (Figure 5). When
the helix was not visible, turns populated the lower energy
conformers. These structural features allowed the peptide to
assume the required receptor-bound conformation and antago-
nize adiponectin actions. The somewhat increased flexibility of
ADP355 may explain the slightly improved binding constants
relative to Chex-DSer-8 (ADP400).
Based on the present REMD data, three novel AdipoR ago-
nists were designed (Table 1 and Discussion). Two of these were
dimeric structures with one of them having a head-to-tail cyclic
structure (peptide 398), and the other being a linear branched
dimer C-terminally tethered to a diamino-butyric acid scaf-
fold (peptide 399). The third peptide was a trimer of ADP355
(ADP500, 500). The free energy surface of the linear dimeric pep-
tide 399 using the first two principal components, dPCA1 and
dPCA2, of chain A were similar to those of the other three pep-
tides and exhibited multiple minima (Figure 5). However, here
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the lowest energy structure was in a deep well and the two pep-
tide chains were in a twisted anti-parallel β-sheet conformation
(Figure 6). The β-sheet conformation was also a feature of the
third lowest energy structure, however, here the two chains were
in parallel orientation. In other minima the individual chains
showed similar structural features to the single chain peptide 355.
ACTIVITY OF THE SECOND GENERATION AdipoR AGONISTS
The activity of the dimeric and trimeric peptides 398, 399, and
500 was tested in both cancer cell lines of this study. First the K562
CML cell line was used that is less responsive to ADP355 (355)
treatment than MCF-7 BC cells and thus the efficacy differences
among analogs were expected to be easier to observe. The cyclic
dimer 398 inhibited K562 proliferation to a similar extent as the
parent ADP355 analog (Figure 1). Maximal efficacy was detected
at 1μM peptide concentration with a relative IC50 of 300 nM.
In contrast, the linear branched dimer (ADP399) exhibited sig-
nificantly improved activities, with maximal effects at 100 nM
and IC50 value of 10 nM (Figure 2). Similar to the observations
regarding the parent peptide ADP355, in later assays/cell passage
the maximum activity of ADP399 was improved, and was as low
as 10 nM. The 20-fold increase (molar terms, 8-fold increase in
w/v terms) in the activity upon lead optimization is strikingly
similar to the improvement in cancer cell proliferation inhibi-
tion when going from first to second generation ObR antagonists
(Otvos et al., 2011b,c). As not only the concentration-activity
curve shapes were identical but all three AdipoR agonist peptides
(having identical base sequences) restricted tumor cell growth to
an identical degree (in the presented assay at 40%) at their maxi-
mal activity concentration, we assume that the mode of action of
ADP355, the cyclic dimer and the linear dimer are also identical.
The branched trimer (ADP500) was inactive against K562 cells up
to 1μM concentration.
FIGURE 6 | Lowest energy backbone structure of peptides. (A) Native
peptide 25; (B) monomeric agonist peptide 355; (C) antagonist peptide
400; (D) branched dimeric peptide 399. N indicates the N-terminus of a
peptide chain, NA, and NB on (D), respectively, indicate the N-terminus of
chains A and B. Color codes for secondary structures: pink, α-helix; blue,
310-helix; yellow, β-sheet; cyan, β-bend; gray, random meander.
For MCF-7 cells, significant (>15%) growth inhibition was
observed for ADP355 at 10 nM and the linear dimer between
100 pM and 10 nM concentrations (Table 3). The approximately
10-fold improved activity of ADP355 compared to our earlier
report (Otvos et al., 2011a) and Figure 4 of this account is likely
due to slightly different experimental conditions. In this measure,
the cyclic dimer appeared to be less efficacious against MCF-7
cell proliferation than the original peptide ADP355. Nevertheless,
againstMCF-7 cells, similar to K562, the linear dimer was bymag-
nitudes more active than any of the other two peptides (Table 3).
Addition of the third ADP355 chain in peptide ADP500 (500)
did not provide any growth inhibitory advantage over the lin-
ear dimer at the 100 pM–10 nM concentration range. In fact at
10 nM concentration, the activity was found similar to the base
peptide ADP355. Due to the significantly increased synthetic dif-
ficulties and costs of ADP500 compared to ADP355 and ADP399,
the trimer was no longer studied.
Similar to the neutralization of the growth restricting effects of
ADP355, the AdipoR antagonist Chex-DSer-8 (400) fully coun-
teracted the activity of the linear dimer (399). During yet another
repetition of this 3-day growth inhibition assay, at 10 nM concen-
tration, the linear dimer reduced the number of viable MCF-7
BC cells by 25%, but when the cells were co-treated with the lin-
ear dimer (ADP399) and the Chex-D-Ser-8 (ADP400) (both at
10 nM), the number of cells was practically identical to that in
untreated cultures (1% reduction). This data indicates that (i)
the linear dimer and Chex-DSer-8 interact with the same recep-
tor, and (ii) that the antagonist peptide (400) does not exert
pro-mitogenic properties at lower concentrations.
SERUM STABILITY OF AdipoR AGONISTS
Peptide ADP355 (355) is remarkably stable in mouse serum
(Otvos et al., 2011a). Based on the degradation kinetics in diluted
serum, the half-life in whole plasma is estimated at 75min. To
assess the pharmaceutical utility of the new adiponectin pep-
tides here we compared the degradation kinetics of two AdipoR
agonists in undiluted mouse serum. For ADP355, experimen-
tal data provided proof for even more extensive protease resis-
tance than the calculations suggested, exhibiting a serum half-life
of 180min (data not shown). This stability level is quite high
Table 3 | Inhibition (percent of untreated control) of MCF-7 BC cell
proliferation by adiponectin active site analogs.
Peptide ADP355 Cyclic dimer Linear dimer
concentration (355) (398) (399)
10 pM −5 13 −4
100 pM 12 4 27
1nM 8 7 14
10 nM 17 5 16
100 nM 2 −1 1
The table shows the mean of two independent experiments, each ran in one
plate, in duplicates with multiple readings. Very significant (>25%, marked in
bold and italics) and significant (>15%, marked in italics) growth inhibition was
observed for ADP355 at 10 nM and the linear dimer between 100 pM and 10 nM
concentrations.
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among peptide therapeutics, and is likely due to the incor-
poration of 4 unnatural amino acid moieties, including three
D-residues that significantly improve peptide stability (Powell
et al., 1993). The linear branched dimeric construct 399 was
somewhat less stable indicating that the modifications aimed at
increasing the activity reduced the resistance to proteolytic degra-
dation but in general kept the analog among the most stable
peptide drug leads. The half-life of the linear dimer ADP399 was
55min with 16% intact peptide still present after 2 h incuba-
tion with mouse serum. The cyclic dimer precipitated during the
assay procedure, and thus its quantities could not be accurately
measured.
BIODISTRIBUTION
Immediately (1min handling +1min exposure) upon ip admin-
istration to an Skh1 mouse, N-terminally DY675-labeled peptide
ADP355 (355) was distributed into the usual peptide elimina-
tion organs (Klootwijk et al., 1997): the kidneys, the urinary
bladder, the liver, and the rectum (Figure 7). In addition, the
labeled peptide migrated into all tissues, albeit less efficaciously.
Apparently ADP355 was quickly eliminated from the circulation
as at 10min and beyond it was observable only in the kidney
and the bladder (Figure 7). Importantly, at the earliest time-
point ADP355 was observed in the brain area, similarly to our
ObR response modifier peptides (Otvos et al., 2011b; Beccari
et al., 2013). While in all these assays it cannot be excluded that
cleaved fluorophore skews data interpretation, the leptin peptides
and an antimicrobial peptide labeled in an identical manner dis-
play clearly different biodistribution patterns (Otvos et al., 2008;
Rozgonyi et al., 2009). The branched linear dimer peptide 399
was distributed less actively and remained in the peptide elimi-
nation organs throughout the examination procedure (Figure 7).
The increased size of the dimer compared to the monomer may
explain the reduced ability to enter tissues.
A markedly different picture emerged when the two peptides
were administered sc. Peptide ADP355 (355) was clearly bet-
ter absorbed (compared to ip administration) because strong
and homogenous biodistribution could be observed even at the
10min time point (Figure 7). Remarkably, upon sc administra-
tion the branched linear dimer was retained throughout the body
in the entire 60-min examination period (Figure 7). Although at
the hour time point significant amounts of peptides were already
migrated to the kidneys and the bladder, still strong remain-
ing staining was observed in the lungs, upper abdomen, and the
brain. Judged from the biodistribution pattern, the most promis-
ing analog for in vivo efficacy studies is the branched linear dimer,
administered sc.
DISCUSSION
When removed from the protein environment, earlier molecu-
lar dynamics studies indicate that the isolated native adiponectin
active site loses the β-pleated sheet character it adopts in the
FIGURE 7 | Biodistribution of N-terminally DY675-labeled peptides in
Skh1 hairless mice. The top two rows show the absorption of
peptide ADP355 (355) and the bottom two rows of that of the
linear dimer (399). The first and third rows represent intraperitoneal
(ip), the second and fourth document subcutaneous (sc) peptide
administration.
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protein and forms a series of turns (Otvos et al., 2011a). The
designer peptidomimetic, ADP355 appears to fold into a more
stable conformation characterized by a hairpin incorporating
almost the entire peptide. The current molecular modeling
utilized the state-of-the-art REMD simulation protocol with
the AMBER99SB-ILDN-NMR force field (Li and Bruschweiler,
2010). When this force field, together with many other mod-
ern force fields, was tested it achieved the highest accuracy in
extensive benchmark calculations (Beauchamp et al., 2012). The
present calculations agree with the previous one in the higher
conformational freedom of ADP355 compared to the native
sequence with a turn in the middle of the peptidomimetic.
The only difference between the results generated by the two
methods is the increased α-helix and decreased β-sheet con-
tribution to the structure of the native active site after REMD
simulations.
These MD calculations served as base for the design of second
generation AdipoR agonist peptides. As adiponectin circulates
in higher order complexes, we wanted to develop a dimer and
a trimer of the first-in-class AdipoR agonist peptide ADP355.
Higher order multimers were not considered due to anticipated
synthetic difficulties and avoiding potential aggregation of the
identical chains that could be even further strengthened by paral-
lel peptide segments induced by the central hairpin. To show the
importance of the conformational freedom in binding AdipoR,
we designed a linear branched peptide that was expected to
exhibit stronger activity due to the multimeric chain arrange-
ment. To make the ADP355 fragment freely available for recep-
tor binding in the dimeric construct, we C-terminally extended
the monomer sequence by His, the amino acid residue follow-
ing the native Tyr in the active site and a turn-forming Pro
residue. The peptide retained conformational flexibility but the
lowest energy structure is in an anti-parallel β-sheet conforma-
tion, which is most likely preferred by the receptor. The dimer
was designed on a template from the native adiponectin active
site (peptide 25) which is in the adiponectin protein in an anti-
parallel β-sheet conformation (Otvos et al., 2011a). Subsequently,
the improved receptor affinity of the dimer is most likely due
to mimicking the native conformation of adiponectin. We also
designed the same peptide embedded into a cyclic structure. The
cyclic peptide has less conformational freedom and such was
expected to exhibit weaker cellular activities in spite of the mul-
ticopy agonist arrangement. In both new designs we extended
the sequence with a C-terminal His (the native residue following
Tyr that is mimicked by DSer10 in ADP355) and turn-forming
Pro and Asp residues to separate the individual chains within
the same peptide. As the trimer exhibited no cellular therapeu-
tic advantage over the dimer, its conformation was not studied in
detail.
The cellular models used here were selected among those
known to express AdipoR, involve adiponectin in biologi-
cal responses and yield reproducible results in our hands.
Adiponectin protein has been linked to leukemia, lymphoma,
and myeloma in individuals with above-average BMI (Obeid
and Hebbard, 2012). Human-origin K562 CML cells express
both AdipoR forms although at relatively low levels (Ozturk
et al., 2012). Imatinib chemotherapy does not affect AdipoR
expression in K562 cells, suggesting a potential combination
treatment strategy with BCR-ABL tyrosine kinase inhibitors and
AdipoR agonists. In the earliest report on the subject, addition
of adiponectin protein inhibits the relative proliferation rate
(compared to the unrelated human serum albumin) of K562
cells by 9% (Yokota et al., 2000). The higher level of activ-
ity of our peptidic adiponectin fragments on K562 prolifera-
tion reflects the previously observed increased activity of our
agonist using glioma and BC cells compared to the full pro-
tein (Otvos et al., 2011a). Alternatively, processed fragments
of adiponectin exhibit improved cellular activities (vide supra).
While the role of adiponectin in kidney fibrosis and myofi-
broblast differentiation is controversial (Beige et al., 2009; Yang
et al., 2013) the adipokine appears to prevent interstitial fibro-
sis in vivo (Rutkowski et al., 2013) and fibroblast migration
and transition to myofibroblasts in vitro (Cai et al., 2010). Here
we tested whether peptide ADP355 can ameliorate fibrosis by
interfering with differentiation to myofibroblasts, a marker of
activation in fibroblasts. Previous studies suggest that the herein
used renal interstitial fibroblasts isolated from fibrotic rat kid-
neys are more active in terms of proliferation and synthetic
activity than fibroblasts grown from normal kidney (Rodemann
and Muller, 1990) and are therefore a better reflection of their
in vivo counterparts. Importantly, we wanted to compare the
cellular IC50 values of ADP355 across divergent diseases to
obtain a uniform baseline during the improvement of the activity
figures.
The assay repertoire for evaluating the relative efficacy of
adiponectin-based peptides is very limited. Conceivably, short
adiponectin fragments, such as our peptides, further expand
the portfolio of biological responses in adiponectin-sensitive
cells. Thus, with no reliable external control available (includ-
ing endogenously induced or exogenously added full-sized
adiponectin protein), we had to compare the activity of the new
derivatives to the base peptide ADP355 (355), very heavily stud-
ied for its in vitro and in vivo functions earlier (Otvos et al.,
2011a; Pepping et al., 2014), in cancer cell lines whose easily
measurable proliferation properties were repeatedly shown to be
characteristic to typical adiponectin functions (Jarde et al., 2009;
Ozturk et al., 2012). The cellular models meant to investigate
adiponectin receptor-mediated biological functions. Originally
we used siRNA knockdown to show that ADP355 affects AdipoR
responses, especially those proceeding through AdipoR1 activa-
tion (Otvos et al., 2011a). Because the peptide analogs studied
in this report have almost identical sequences as ADP355 just
differ in size or valency, we can safely assume that these also influ-
ence AdipoR signaling. With all the cell line and assay condition
dependence of signature AdipoR cellular responses (Wijesekara
et al., 2010; Otvos et al., 2011a) it is very difficult to iden-
tify and test characteristic signaling events. Moreover, in our
hands, as well as in the literature (cf INTRODUCTION), var-
ious adiponectin protein preparations induce diverse cellular
responses, making almost impossible to identify a standard assay
that would prove AdipoR activation or deactivation. The most
straightforward measure of peptide-receptor interactions would
be the studying of direct molecular binding. We attempted to
accomplish that with DY675-labeled ADP355 (355) and linear
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dimer (399) and a commercially available AdipoR1 preparation
(Novus Biochemicals) using both enzyme-linked immunosor-
bent (ELISA) and dot-bot type assays. Due to the notorious
insolubility of AdipoR we immobilized it to the solid surfaces
and to the reduction of the binding efficacy when labels are
near to adipokine active sites (Otvos et al., 2014) we focused
on 10 nM—1μM soluble labeled peptides. Unfortunately while
at 100 nM we detected very low level of specific binding (more
for ADP399 than for ADP355), at 1μM both DY675 conjugated
peptides adhered to the plastic and paper surfaces in spite of pre-
vious blocking of these sites and extensive washing with aqueous
buffers.
The ADP399 linear dimer seems to fulfill the criteria of con-
temporary drug leads. The 10 nM relative IC50 value is quite
promising in CML therapy (or in fact any other diseases where
the adiponectin receptor needs activation) on its own right.
Significantly, the improvement in efficacy was not accompanied
with major loss of metabolic stability. Although ADP355 is more
stable in serum than the linear dimer, the serum metabolites
of the dimer may also include active fragments. A preliminary
mass spectrometry study of the serum metabolites of the linear
branched dimer peptide 399 suggested two degradation path-
ways. In one of them one of the chains remains intact, while in
the other chain the N-terminal five (2233 Da) and six (2069 Da)
residues are cleaved. Thus, a complete chain, with full AdipoR
agonist properties is still present among the degradation prod-
ucts. This is very similar how the antibacterial peptide A3-APO
dimer, which is similarly built on a C-terminal Dab scaffold,
breaks down in vivo at the tethering point into two complete pep-
tide chains that retain full in vitro and in vivo activities (Noto
et al., 2008).
Why the ADP399 linear branched dimer (399) is more active
than the monomer 355 (ADP355) needs further experimenta-
tion. We designed the dimers because adiponectin protein cir-
culates in trimeric and higher order complexes. The dimeric
structure seems to induce an antiparallel β-pleated sheet struc-
ture (Figure 6D) but under our experimental conditions it did
not readily form aggregates. Furthermore, peptide dimers are
generally more active than single chain analogs, even in appli-
cations when the native parent peptide is monomeric (Cudic
et al., 2002; Janssen et al., 2002; Aggarwal et al., 2006). Potentially
simultaneous inhibition of multiple receptor copies, or in general
terms interaction with multiple copies of cell surface structures,
offers a therapeutic advantage for peptide drugs. MD calculations
suggested that the charge density-based binding affinity, stable
covalent dimerization, and the ability to dimerize and adopt
a well-defined structure are important physicochemical proper-
ties of a C-terminally tethered antibacterial peptide that exhibits
improved activity relative to the monomeric version (Zhou et al.,
2011). The cyclic AdipoR agonist dimer 398 did aggregate dur-
ing the serum stability assay, but we did not identify the exact
step when this aggregation occurred. The slight loss of activity
compared to ADP355 could be due to the restriction in confor-
mational freedom, to aggregation, or both. The trimeric variant
(500) had an activity profile similar to those of other peptides
in this study against MCF-7 cells without full inhibition by the
AdipoR antagonist (400) suggesting potentially additional targets.
Many peptide drugs, including our antibacterial peptides,
demonstrate inferior in vivo efficacy when added sc com-
pared to ip administration and we explained this with the
poor drug absorption during the sc route (i.e., the peptide
remains at the injection site as a depot) (Rozgonyi et al., 2009).
Notable exceptions to this rule are insulin that is adminis-
tered at home sc, and our leptin receptor response modifier
peptide derivatives (Knappe et al., 2008; Beccari et al., 2013).
In fact, our leptin receptor antagonist Allo-aca is more effi-
cacious in animal models of BC when added sc than when
administered ip (Otvos et al., 2011b). The explanation of the
improved biodistribution of adipokine analogs lies in the very
extensive vascularization of the subcutaneous adipose tissue
(Gaelekman et al., 2011). Capillary density per adipocyte is
higher in subcutaneous than in visceral tissue offering fast and
widespread absorption into the systemic circulation upon sc
drug administration. In addition, overexpression of adiponectin
in mice was shown to result in highly vascularized subcuta-
neous adipose tissue (Rutkowski et al., 2009), further improv-
ing the potential success of adiponectin-based drugs upon sc
inoculation.
This is a first report on the development on an AdipoR
antagonist peptide. Due to the high sequence similarities pep-
tide ADP400, Chex-DSer-8 (400), is almost as efficacious an
antagonist as the parent ADP355 (355) is an agonist. Because
adiponectin restricts MCF-7 cell proliferation, these cells express
just small amounts of the adipokine (Jarde et al., 2009). At the
lowest concentration that elicits maximal activity (100 nM) the
Chex-DSer-8 produces minor mitogenic response in MCF-7 cells
(depending upon the origin of the test cell population), perhaps
by antagonizing the autocrine adiponectin loop. Alternatively,
ADP400, Chex-DSer-8, can act as an inverse AdipoR agonist. An
analogy with ObR antagonist peptides may justify this assump-
tion. In most tumor cells, the ObR antagonist Allo-aca exhibits
a large concentration window (>1000-fold) from going from
antagonist to agonist (Otvos et al., 2011b,c). Against the K562
CML cell line which expresses low levels of ObR (Ozturk et al.,
2012), however, Allo-aca either retains anti-proliferative activ-
ity without exogenous leptin added, or exhibits a narrower
concentration window (approximately 100-fold) before it stim-
ulates rather than inhibits cell growth depending upon the
nutrient strength of the media or the cell passage (vide supra)
(Otvos et al., 2014). Apparently at low receptor expression lev-
els adipokine receptor antagonists may exhibit inverse agonist
properties. In any event, with submicromolar activities, pep-
tide Chex-DSer-8 should be able to perform well all across
medicine as an AdipoR target validation tool. As a therapy
agent, for treating arthritic diseases lead optimization should be
able to improve the activity 10–50 fold similar to our second
generation AdipoR agonists reported herein, as well as opti-
mized ObR agonist and antagonist peptides we developed earlier
(Kovalszky et al., 2010; Otvos et al., 2011b). A remote possi-
bility for the therapeutic use of an AdipoR antagonist is type
1 diabetes, a condition in which elevated levels of both the
receptor and the ligand were found in patients and disease-
carrying experimental animals (Karamifar et al., 2013; Lin et al.,
2013).
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